Fig. 5: YAP signaling with the potential to involve in the diversity of liver cancer.

A Integrative analysis of data from the scRNA-seq screen with publicly available databases of liver cancer from the TCGA. B Heatmap of genes with increased expression in tumor cells from diversity-high group. The color of each group represents the average gene abundance. C Gene set enrichment analysis (GSEA) analysis showing significant positive enrichment of YAP signaling with upregulated genes in tumor cells from the diversity-high group. D Kaplan-Meier survival analysis of patients with YAP at high or low protein levels from The Cancer Proteome Atlas (TCPA). E, F Staining of YAP in tumor tissues from liver cancer patients and rats treated with DEN up to 16 weeks. Bars, 100 µm. G t-SNE plots showing the expression levels of YAP, CTGF, CYR61 and MYC in tumor cells of diversity-high and diversity-low groups. H Representative cores of YAP, BMI1, and SOX4 staining in the tissue microarray. Bar, 100 μm. I Pearson correlation analysis of the mRNA levels between BMI1/SOX4 and YAP in liver cancer patients from the TCGA database. At least two independent experiments were performed for all data. Quantified data are presented as the means ± SD. Unpaired Student’s t tests were used for comparing two variables and one-way ANOVA was used for comparing multiple variables. *P < 0.05; **P < 0.01; ***P < 0.001; n.s, no significance in comparison with the control group. See also Fig. S3.